The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News

NeurologyLive® Friday 5 — January 30, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 30, 2026.

AAN Publishes First-Ever Guideline for Functional Seizure Care Management Marco Meglio

The AAN's new guideline enhances diagnosis and management of functional seizures, emphasizing psychological interventions and addressing care gaps for better patient outcomes.

Taysha Doses First Patient in Pivotal Trial for Rett Syndrome Gene Therapy TSHA-102, Aligns With FDA on BLA Plans Noah Stansfield

Specifically, the alignment relates to a separate, planned clinical trial referred to as ASPIRE.

Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial Noah Stansfield

With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported in the study.

Higher CTE Stages Linked to Increased Dementia Risk, Postmortem Analysis Shows Louie Pasculli

A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.

New 3-Year EMBARK Data Highlights Continued Therapeutic Effect of Gene Therapy Elevidys in Duchenne Marco Meglio

New findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.

Todays Updates

VMAT2 Inhibitor NBI-1065890 Heads to Phase 2 Study in Tardive Dyskinesia Marco Meglio

Neurocrine Biosciences launches a Phase 2 trial for NBI-1065890, targeting tardive dyskinesia with promising new treatment options.

NeurologyLive® Brain Games: February 1, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ACTRIMS and its history!

Anti-IL6R Therapy Effective in Reducing NMOSD and MOGAD Disease Activity Louie Pasculli

Anti–interleukin-6 receptor therapy may offer a new treatment option for patients with NMOSD and MOGAD who do not respond to rituximab, according to new findings.

This Week on NeurologyLive® — February 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

FDA Clears KORU FreedomEDGE System to Administer Rozanolixizumab-noli in gMG Louie Pasculli

The FDA approves the FreedomEDGE infusion platform for rozanolixizumab, enhancing treatment options for generalized myasthenia gravis in clinical settings.

National Women Physicians Day: Janis Miyasaki, Neuropalliative Care, and Advancing Women Leadersip Marco Meglio, Janis Miyasaki, MD, MEd, FRCPC, FAAN

Janis Miyasaki, MD, MEd, FRCPC, FAAN, a pioneer in neuropalliative care, provided clinical thoughts and perspectives on National Women Physicians Day and the ways to promote women leadership within the neurology field.

Women Physicians Day 2026: Supporting Women With MS Through Reproductive and Life Stage Transitions Isabella Ciccone, MPH, Katrina Bawden, MSN, MSCN, FNP-C, Parisa Khosravi, DO, April Erwin, MD

In honor of National Women Physicians Day, held February 3, 2026, a trio of women clinicians highlighted the importance of individualized care for women living with multiple sclerosis.

Todays Updates

VMAT2 Inhibitor NBI-1065890 Heads to Phase 2 Study in Tardive Dyskinesia Marco Meglio

Neurocrine Biosciences launches a Phase 2 trial for NBI-1065890, targeting tardive dyskinesia with promising new treatment options.

NeurologyLive® Brain Games: February 1, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ACTRIMS and its history!

Anti-IL6R Therapy Effective in Reducing NMOSD and MOGAD Disease Activity Louie Pasculli

Anti–interleukin-6 receptor therapy may offer a new treatment option for patients with NMOSD and MOGAD who do not respond to rituximab, according to new findings.

This Week on NeurologyLive® — February 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

FDA Clears KORU FreedomEDGE System to Administer Rozanolixizumab-noli in gMG Louie Pasculli

The FDA approves the FreedomEDGE infusion platform for rozanolixizumab, enhancing treatment options for generalized myasthenia gravis in clinical settings.

National Women Physicians Day: Janis Miyasaki, Neuropalliative Care, and Advancing Women Leadersip Marco Meglio, Janis Miyasaki, MD, MEd, FRCPC, FAAN

Janis Miyasaki, MD, MEd, FRCPC, FAAN, a pioneer in neuropalliative care, provided clinical thoughts and perspectives on National Women Physicians Day and the ways to promote women leadership within the neurology field.

Women Physicians Day 2026: Supporting Women With MS Through Reproductive and Life Stage Transitions Isabella Ciccone, MPH, Katrina Bawden, MSN, MSCN, FNP-C, Parisa Khosravi, DO, April Erwin, MD

In honor of National Women Physicians Day, held February 3, 2026, a trio of women clinicians highlighted the importance of individualized care for women living with multiple sclerosis.

Latest News

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 30, 2026.

The AAN's new guideline enhances diagnosis and management of functional seizures, emphasizing psychological interventions and addressing care gaps for better patient outcomes.

Specifically, the alignment relates to a separate, planned clinical trial referred to as ASPIRE.

With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported in the study.

A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.

New findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.

News All Time

Integrating GFAP Improves Accuracy of Large Vessel Occlusion Detection in Acute Stroke Settings Louie Pasculli

In a recently published study, integrating prehospital GFAP measurements with established stroke scales significantly improved the accuracy of large vessel occlusion detection in patients with acute stroke.

Phase 1/2a Findings Lend Support for BB-301 in Oculopharyngeal Muscular Dystrophy Marco Meglio

Benitec Biopharma reveals promising results for BB-301, a gene therapy showing significant improvements in swallowing function for OPMD patients.

Evaluating Durable Dysphagia Outcomes in OPMD: Insights From Early BB-301 Clinical Data Marco Meglio

Jerel Banks, MD, PhD, chief executive officer of Benitec Biopharma, reviews early phase 1b/2a clinical signals, mechanism, and next steps for BB-301 in oculopharyngeal muscular dystrophy.

NeurologyLive® Friday 5 — January 23, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 23, 2026.

NeurologyLive® Brain Games: January 25, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ALS Treatment pathways!

FDA Grants Orexin Agonist Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 Isabella Ciccone, MPH

Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.

Episode 159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines Marco Meglio, Benjamin Tolchin, MD, MS, FAAN

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]

AskBio’s Late-Onset Pompe Disease Gene Therapy AB-1009 Cleared for Phase 1/2 Trial Noah Stansfield

AskBio noted that AB-1009 also recently received fast track and orphan drug designations from the FDA.

NLX-112 Shows Safety and Tolerability in Phase 2a Parkinson Trial, Supporting Further Development Louie Pasculli

A phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.

Migraine Medication Zavegepant Safe and Well Tolerated in Lactating Women, Phase 1 Study Shows Louie Pasculli

A Phase 1 study in healthy lactating women found that a single 10‑mg dose of zavegepant nasal spray was generally safe, well tolerated, and resulted in minimal infant exposure through breast milk.

Levacetylleucine Meets Primary and Secondary End Points in Phase 3 Ataxia-Telangiectasia Study Isabella Ciccone, MPH

IntraBio reported that levacetylleucine showed symptom improvement in the phase 3 IB1001-303 study for ataxia-telangiectasia, and it intends to proceed with regulatory submissions in multiple regions.

NeuroVoices: Sneha Mantri, MD, MS, on Addressing Depression and Anxiety in Parkinson Care Marco Meglio

The chief medical officer at the Parkinson’s Foundation detailed how mood and behavioral symptoms shape quality of life in Parkinson disease and how clinicians can better identify and manage them.

Early Opicapone Initiation in Parkinson Leads to Continued Long-Term Therapeutic Benefits Marco Meglio

Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.

FDA Requests HOPE-3 Clinical Study Report for Deramiocel BLA in DMD Cardiomyopathy Isabella Ciccone, MPH

The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.

Low-Dose Opioids Show Long-Term Dose Stability, Effectiveness in Augmented Restless Legs Syndrome Louie Pasculli

A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.

Dopamine D3 Receptor Mesdopetam Maintains Antidyskinesia Effects Despite Failure to Improve Parkinson Disease ON Time Marco Meglio

A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.

Recommended News For You

New BiTE Agent for Small Cell Lung Cancer Approved by the FDA.

Photoacoustic spectral analysis for gaining knowledge of the tumor microenvironment.

In inflammatory breast cancer, ER beta regulates estrogen signaling.

Discovery of a new biomarker for early detection of bladder cancer in both dogs and humans

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

Geriatric Assessment, QoL Correlate With OS in Older Patients with Pancreatic Cancer

Extracellular matrix pathway emerges as treatment target for pediatric cancer

Recommended Articles For You

Liquid Biopsy in Oncology: Innovations in Cancer Detection, Monitoring, and Clinical Use 

The Potential of Amifostine in Cancer Treatment: A Revolutionary Breakthrough 

Paving the Path to Precision: A Review of TAR-200 in the Evolving Bladder Cancer Landscape 

ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.

2.

Pancreatic cancer RNA vaccine shows durable T cell immunity

3.

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

4.

In schizophrenia, sexual dysfunction is frequent.

5.

Scientists identify dual protein targets to weaken pancreatic cancer defenses

1.

Optimizing the Diagnosis and Treatment of Hematological Diseases Through Artificial Intelligence

2.

Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients

3.

Machine Learning in Genomic Analysis for Early Lung Cancer Detection: Key Advances and Insights

4.

Understanding Phyllodes Tumor: Symptoms, Diagnosis, and Treatment Options

5.

Unlocking the Potential of Immune Checkpoint Inhibitors: A Pioneering Case Series on the Role of Immunotherapy in Microsatellite-Instability-High Colorectal Cancer

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

2.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II

3.

Thromboprophylaxis In Medical Settings

4.

Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment

5.

Navigating the Complexities of Ph Negative ALL - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot